Home › Amyotrophic Lateral Sclerosis › NCT06735014
Multicenter ALS Imaging Study
Multicenter Longitudinal Imaging in ALS for Disease Biomarker Development
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
For participants with ALS: * \< 36 months since onset of symptoms * Definite, probable, lab-supported probable, or possible ALS by El Escorial criteria OR definite, probable, or possible ALS per Awaji-Shima criteria OR meets Gold Coast criteria * Forced vital capacity within the last 90 days ≥ 60% of the predicted value * Able to consent for themselves * Able to read and speak English * Clear of any contraindications for MRI Exclusion Criteria: * Individuals will be excluded if they have any condition that makes MRI unsafe or if they are unable to comply with instructions. * All participants will undergo a neurologic examination at enrollment. Control participants with clinically significant abnormal findings on neurological examination will be excluded from the study.
About the study
This is a multi-site study of ALS participants and healthy controls who will undergo brain and cervical spine MRIs and NfL blood testing at up-to 4 time points over the course of a year. The primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.
What is being tested
- Magnetic Resonance Imaging (diagnostic test)
- Plasma neurofilament light chain (NfL) quantification (diagnostic test)
Sponsor: University of Minnesota · Participants: 90 · Started: Sep 15, 2024
Contact the study team
- Melisa Bailey, MS · Phone: 612-624-4911
Official record on ClinicalTrials.gov — NCT06735014
Locations in the U.S.
| Florida | University of Florida, Gainesville |
| Illinois | Northwestern University, Evanston |
| Minnesota | University of Minnesota, Minneapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.